Receptor-Mediated Transcytosis (RMT)

Migration, Crosslink

📖

Receptor-Mediated Transcytosis (RMT)

active

wiki page Created: 2026-04-02T07:20:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-receptor-mediated-transc

📖 Wiki Page

mechanism3380 wordssynced 2026-04-02

Receptor-Mediated Transcytosis (RMT)

Overview

Receptor-mediated transcytosis (RMT) is a specialized transcellular transport mechanism that enables the movement of macromolecules across cellular barriers, most notably the blood-brain barrier (BBB). This process leverages specific receptor-ligand interactions to shuttle cargo from the luminal (blood) side to the abluminal (brain) side of endothelial cells, representing one of the most promising approaches for delivering therapeutic agents to the central nervous system [1](https://pubmed.ncbi.nlm.nih.gov/26230724/). [@herz1992]

The significance of RMT in neurodegenerative disease therapy cannot be overstated. Despite the identification of numerous potential therapeutic targets for Alzheimer's disease, Parkinson's disease, and other neurological disorders, the BBB has historically prevented most large-molecule drugs from reaching their intended sites of action. RMT offers a biological solution to this problem by exploiting endogenous transport pathways that normally mediate the brain uptake of essential nutrients and proteins. [@nessler2022]

The historical development of RMT as a drug delivery concept traces back to the pioneering work of William Pardridge in the 1980s, who first demonstrated that exogenous proteins could be transported across the BBB via endogenous receptor systems [2](https://pubmed.ncbi.nlm.nih.gov/3024634/). This foundational work established the theoretical basis for what would become one of the most actively pursued strategies in CNS drug development. [@sarkar2020]

...

Receptor-Mediated Transcytosis (RMT)

Overview

Receptor-mediated transcytosis (RMT) is a specialized transcellular transport mechanism that enables the movement of macromolecules across cellular barriers, most notably the blood-brain barrier (BBB). This process leverages specific receptor-ligand interactions to shuttle cargo from the luminal (blood) side to the abluminal (brain) side of endothelial cells, representing one of the most promising approaches for delivering therapeutic agents to the central nervous system [1](https://pubmed.ncbi.nlm.nih.gov/26230724/). [@herz1992]

The significance of RMT in neurodegenerative disease therapy cannot be overstated. Despite the identification of numerous potential therapeutic targets for Alzheimer's disease, Parkinson's disease, and other neurological disorders, the BBB has historically prevented most large-molecule drugs from reaching their intended sites of action. RMT offers a biological solution to this problem by exploiting endogenous transport pathways that normally mediate the brain uptake of essential nutrients and proteins. [@nessler2022]

The historical development of RMT as a drug delivery concept traces back to the pioneering work of William Pardridge in the 1980s, who first demonstrated that exogenous proteins could be transported across the BBB via endogenous receptor systems [2](https://pubmed.ncbi.nlm.nih.gov/3024634/). This foundational work established the theoretical basis for what would become one of the most actively pursued strategies in CNS drug development. [@sarkar2020]

The Blood-Brain Barrier as a Therapeutic Hurdle

Structure and Function of the BBB

The blood-brain barrier represents a dynamic interface between the peripheral circulation and the central nervous system, comprising specialized endothelial cells connected by tight junctions, pericytes embedded in the basement membrane, and astrocytic end-feet ensheathing the neurovascular unit [3](https://pubmed.ncbi.nlm.nih.gov/22890237/). [@tjia2018]

Endothelial Tight Junctions: The BBB endothelial cells exhibit extremely tight intercellular junctions that restrict paracellular diffusion of polar molecules. Key junctional proteins include claudins (particularly claudin-5), occludin, and junctional adhesion molecules (JAMs). These proteins form a continuous seal that virtually eliminates the space between endothelial cells for molecules larger than ~400 Da. [@van2017]

Transcellular Transport: The BBB employs multiple specialized transport mechanisms: [@kariolis2020]

Carrier-mediated transport (CMT) for nutrients like glucose and amino acids
Receptor-mediated transcytosis (RMT) for larger endogenous molecules
Adsorptive-mediated transcytosis (AMT) for cationic molecules
Active efflux transporters (P-glycoprotein, BCRP, MRPs) that limit brain penetration

The Neurovascular Unit: Modern understanding recognizes the BBB as part of a larger neurovascular unit that includes neurons, astrocytes, pericyts, and microglia. This unit maintains brain homeostasis and responds dynamically to neurological insults [4](https://pubmed.ncbi.nlm.nih.gov/20079950/). [@larrayoz2014]

Implications for Drug Delivery

The BBB's physiological functions create a significant challenge for CNS drug development: [@ravi2015]

| Property | Small Molecules | Large Molecules (Proteins, Antibodies) | Nanoparticles | [@gera2017]
|----------|-----------------|----------------------------------------|---------------| [@jiang2017]
| BBB Penetration | Variable (logP-dependent) | <0.1% of administered dose typically | <1% typically |
| Transport Mechanism | Passive diffusion, CMT | RMT (limited) | Limited RMT |
| Therapeutic Window | Wider | Very narrow | Narrow |

This limitation has led to the "valley of death" in CNS drug development, where promising therapeutic candidates fail due to inadequate brain exposure. RMT provides a biological solution by hijacking the very mechanisms the BBB uses for essential nutrient delivery.

Molecular Mechanism of Receptor-Mediated Transcytosis

The RMT Process

Receptor-mediated transcytosis involves a multi-step process that can be divided into several distinct phases:

Step 1: Receptor Recognition and Binding
The process begins with the specific binding of a ligand to its cognate receptor on the luminal (apical) surface of the endothelial cell. This binding event is typically of high affinity and saturable, distinguishing RMT from non-specific adsorptive transcytosis. Examples of naturally occurring RMT ligands include transferrin, insulin, and LDL particles [5](https://pubmed.ncbi.nlm.nih.gov/12089441/).

The binding affinity (KD) typically ranges from 1-100 nM for effective transcytosis. Too-high affinity can lead to lysosomal sequestration, while too-low affinity results in insufficient receptor engagement.

Step 2: Clathrin-Mediated Endocytosis
Following ligand binding, the receptor-ligand complex invaginates and is internalized via clathrin-coated pits. This process is dynamin-dependent and requires the coordinated activity of multiple endocytic proteins including clathrin adaptors (AP-2), dynamin, and amphiphysin [6](https://pubmed.ncbi.nlm.nih.gov/19028540/).

The formation of clathrin-coated vesicles involves:

Nucleation of clathrin pits by AP-2 adaptors
Cargo selection through sorting motifs
Membrane curvature mediated by clathrin triskelions
Vesicle scission by dynamin GTPase

Step 3: Endosomal Trafficking
Once internalized, the receptor-ligand complex enters early endosomes (pH ~6.5). The acidic environment of the endosome triggers conformational changes in many receptors, leading to cargo sorting. Some receptors are recycled back to the plasma membrane, while others are targeted for degradation or transcytosis [7](https://pubmed.ncbi.nlm.nih.gov/19229963/).

Key sorting decisions include:

Retrograde trafficking to trans-Golgi network
Recycling to the plasma membrane
Routing to the transcytotic pathway
Delivery to lysosomes for degradation

Step 4: Transcytotic Transport
For RMT to proceed, the receptor-ligand complex must be sorted into the transcytotic pathway. This involves trafficking through the recycling endosome (pH ~6.0) and ultimately reaching the basolateral (abluminal) membrane. The molecular mechanisms governing this sorting decision remain an active area of investigation [8](https://pubmed.ncbi.nlm.nih.gov/25486855/).

Transcytotic trafficking is characterized by:

Movement through tubular recycling endosomes
Avoidance of lysosomal targeting
Retention of receptor integrity for multiple transcytosis events

Step 5: Exocytosis and Release
At the basolateral membrane, the cargo is released into the extracellular space of the brain. This step involves fusion of the transport vesicle with the plasma membrane, releasing the ligand while typically resulting in receptor recycling back to the luminal surface [9](https://pubmed.ncbi.nlm.nih.gov/10644228/).

Key Receptors Involved in RMT

| Receptor | Natural Ligand | Brain Expression | Therapeutic Potential |
|----------|---------------|------------------|----------------------|
| TfR1 | Transferrin | Brain capillary endothelium | High - already in clinical use |
| TfR2 | Transferrin | Lower expression | Moderate |
| Insulin Receptor | Insulin | High expression | Moderate - safety concerns |
| IGF1R | IGF-1 | Moderate expression | Limited by IGF-1 activity |
| LRP1 | ApoE, α2-macroglobulin | High expression | Very high - multiple cargo options |
| LRP2 (Megalin) | ApoE, lipoproteins | Limited BBB expression | Moderate |
| RAGE | AGEs, HMGB1 | Induced expression | Low - pro-inflammatory |
| LDLR | LDL, VLDL | Moderate expression | Limited cargo capacity |

Transferrin Receptor (TfR1) in Detail

The transferrin receptor (TfR1) represents the most extensively studied RMT target for brain delivery. This 180 kDa homodimeric type II membrane protein is highly expressed on brain capillary endothelial cells and is essential for iron delivery to the brain [10](https://pubmed.ncbi.nlm.nih.gov/2742782/).

Structural Features:

Extracellular domain that binds diferric transferrin
Single transmembrane helix
Short cytoplasmic tail containing internalization motifs

Physiological Function:

Imports iron as Fe³⁺ complexed to transferrin
Regulated by cellular iron status
Essential for brain development and function

Therapeutic Exploitation:

Antibodies against TfR enable receptor-mediated transcytosis
Bispecific antibody approach shows 10-30-fold brain exposure increase
Binding affinity optimization is critical for efficiency

LRP1 and LRP2 (Megalin)

The low-density lipoprotein receptor-related proteins (LRPs) represent a family of large multi-ligand receptors with significant potential for brain drug delivery [11](https://pubmed.ncbi.nlm.nih.gov/11238007/).

LRP1:

Expresses abundantly on brain capillary endothelium
Binds over 40 different ligands including ApoE, α2-macroglobulin, tPA
Undergoes efficient transcytosis of many cargo types
Multiple ligands enable diverse therapeutic conjugation strategies

LRP2 (Megalin):

Originally characterized in kidney proximal tubules
Limited expression at the BBB under normal conditions
Upregulated in certain disease states
Potential for targeted delivery in specific conditions

RMT for Neurodegenerative Disease Therapy

Alzheimer's Disease

Receptor-mediated transcytosis offers particular promise for Alzheimer's disease therapy, as multiple therapeutic candidates require brain delivery:

Anti-Amyloid Antibodies: Monoclonal antibodies targeting amyloid-beta (Aβ) such as lecanemab and donanemab have shown efficacy in clearing plaques, but their brain penetration is limited when administered systematically. Strategies to enhance BBB penetration via RMT include:

Engineering bispecific antibodies with BBB-crossing domains [12](https://pubmed.ncbi.nlm.nih.gov/35698765/)
Using transferrin receptor-mediated delivery of anti-Aβ scFvs
Developing LRP1-targeted delivery systems
Combining antibody fragments with RMT ligand peptides

The lecanemab CLARITY-AD trial demonstrated clinical efficacy, but brain penetration remained a limitation. RMT-enabled next-generation antibodies aim to improve upon these results by achieving higher brain concentrations at lower doses.

Tau-Targeting Therapies: Anti-tau antibodies and small interfering RNA (siRNA) targeting tau require efficient brain delivery. RMT platforms being developed include:

TfR-binding antibody fragments fused to anti-tau single domains
LRP1-mediated delivery of anti-tau siRNA
Nanoparticle-based delivery systems employing RMT ligands
AAV vectors engineered for enhanced BBB transduction

Tau pathology correlates more closely with cognitive decline than amyloid, making tau-targeted therapies a high priority. RMT-enabled delivery could significantly improve the therapeutic index of these approaches.

Secretase Inhibitors: BACE inhibitors such as verubecestat have shown adverse effects when administered at doses required for brain penetration. RMT-enabled delivery could lower required doses by improving brain uptake:

Reduced peripheral exposure may diminish off-target effects
Improved brain-to-plasma ratio enhances therapeutic window
Combination approaches with RMT may enable dose reduction

Neurotrophic Factors: BDNF and other growth factors have neuroprotective properties but do not cross the BBB:

LRP1-mediated BDNF delivery shows promise in preclinical models
TfR-targeted GDNF delivery for Parkinson's disease
NGF delivery for cholinergic neuron preservation

Parkinson's Disease

Parkinson's disease presents unique challenges for RMT-based therapy due to the blood-brain barrier's increased integrity in the substantia nigra and the need to target dopaminergic neurons in the basal ganglia:

α-Synuclein Targeting: Multiple approaches are in development:

Anti-α-synuclein antibodies delivered via TfR-mediated transcytosis [13](https://pubmed.ncbi.nlm.nih.gov/28745428/)
Gene therapy vectors using RMT ligands for enhanced delivery
Small molecule modulators requiring enhanced brain penetration
siRNA and ASO delivery targeting SNCA expression

The failure of several anti-α-synuclein antibody trials has highlighted the challenge of achieving sufficient brain exposure. RMT-enabled antibodies are in development to address this limitation.

Neuroprotective Agents: Growth factors including GDNF and BDNF have shown promise in PD models but require efficient delivery:

LRP1-mediated delivery of neurotrophic proteins [14](https://pubmed.ncbi.nlm.nih.gov/22135164/)
TfR-targeted nanocarriers for GDNF
Cell-penetrating peptides combined with RMT ligands
AAV vectors with engineered RMT ligand pseudotyping

Dopamine Replacement: Levodopa and other dopamine agonists face challenges crossing the BBB:

Targeted prodrugs exploiting amino acid transporters
Nanoparticle encapsulation for sustained release
RMT-enabled delivery of dopamine itself

Amyotrophic Lateral Sclerosis (ALS)

ALS presents particular challenges due to the involvement of both upper and lower motor neurons and the often-observed disruption of the BBB:

SOD1 and C9orf72 Targeting: Gene-silencing approaches require delivery to motor neurons:

TfR-mediated ASO delivery shows promise in preclinical models [15](https://pubmed.ncbi.nlm.nih.gov/29154816/)
AAV vectors with RMT ligand modifications for enhanced CNS tropism
Antibody-antisense conjugates for targeted delivery
Nanoparticle-based siRNA delivery

The tofersen trial for SOD1 ALS demonstrated proof-of-concept for gene silencing, but delivery to spinal motor neurons remains challenging. RMT-enhanced delivery systems are in development to address this need.

Neuroinflammation Modulation: Targeting microglia represents an alternative approach:

LRP1-mediated delivery of anti-inflammatory compounds
Nanoparticle-based targeting of activated microglia
Colony-stimulating factor receptor targeting for microglial modulation

Multiple Sclerosis

While not strictly a neurodegenerative disease, MS involves progressive neuronal loss that could benefit from RMT-enabled delivery:

Anti-inflammatory agent delivery to the CNS
Remyelination promoter delivery
Neuroprotective agent delivery

Engineering RMT Systems for Drug Delivery

Antibody-Based Platforms

TfR-Targeting Antibodies

The transferrin receptor (TfR1) represents the most extensively studied RMT target for brain delivery. Key considerations include:

Binding Affinity: The affinity of TfR-binding antibodies critically determines transcytosis efficiency:

Very high affinity (KD < 1 nM) may lead to lysosomal degradation
Moderate affinity (KD 1-100 nM) optimizes transcytosis
Very low affinity may not sufficiently engage the receptor [16](https://pubmed.ncbi.nlm.nih.gov/30659373/)

This affinity optimization represents a critical design parameter that determines the ultimate success of RMT-enabled therapeutics.

Bispecific Antibody Approach: The most advanced clinical approach uses bispecific antibodies that bind both TfR and the therapeutic target. This strategy has demonstrated:

10-30-fold increase in brain exposure compared to monospecific antibodies
Target engagement in the brain at doses 10-100 fold lower
Potential for treating various neurological conditions [12](https://pubmed.ncbi.nlm.nih.gov/35698765/)

Denali Therapeutics has pioneered the use of the FcRn-mediated transport across the BBB in addition to TfR-mediated approaches, providing multiple complementary mechanisms.

LRP1-Targeting Approaches

LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1) offers advantages over TfR:

Multiple endogenous ligands enabling diverse cargo options
High expression on brain capillary endothelium
Efficient transcytosis of various macromolecules

ApoE-Derived Peptides: Apolipoprotein E (ApoE) is a natural LRP1 ligand:

ApoE mimetic peptides enable LRP1-mediated transcytosis
These peptides can be fused to therapeutic proteins
Clinical trials are underway for various CNS indications [17](https://pubmed.ncbi.nlm.nih.gov/24770858/)

Nanoparticle-Based Delivery

Liposomes and Lipid Nanoparticles

Lipid-based nanoparticles offer versatile platforms for RMT-enabled delivery:

Surface Modification: Incorporating RMT-targeting ligands on nanoparticle surfaces:

Transferrin-conjugated liposomes show enhanced brain uptake
ApoE-functionalized lipid nanoparticles cross the BBB
Angiopep peptides (derived from Kunitz-type protease inhibitor) enhance LRP1-mediated transcytosis [14](https://pubmed.ncbi.nlm.nih.gov/22135164/)

Clinical Translation: Several formulations are in clinical development:

Doxorubicin liposomes for brain tumors
siRNA-lipid nanoparticles for CNS applications
mRNA-lipid nanoparticles for CNS protein expression

Polymeric Nanoparticles

Polymeric nanoparticles offer controlled release characteristics:

PLGA Nanoparticles: Poly(lactic-co-glycolic acid) nanoparticles can be functionalized with RMT ligands:

TfR-binding peptides enhance brain delivery
Surface charge modification affects BBB interaction
Degradation rate can be tuned for sustained release [18](https://pubmed.ncbi.nlm.nih.gov/21324647/)

Cell-Penetrating Peptides and Trojan Horses

Chimeric Toxins as Trojan Horses

The original "Trojan horse" concept utilized naturally occurring toxins that naturally undergo RMT:

Angiopep-2: A peptide derived from the Kunitz-type protease inhibitor that binds LRP1:

Enables transcytosis of conjugated cargo
Has been extensively studied in clinical trials
Used in multiple nanoparticle platforms [14](https://pubmed.ncbi.nlm.nih.gov/22135164/)

ANG1005 (Angiopep-2-paclitaxel) reached Phase 2 clinical trials for brain tumors, demonstrating the clinical potential of this approach.

Tat Peptide: The HIV-1 Tat protein contains a cell-penetrating domain:

Enables both cellular uptake and BBB transcytosis
Requires careful optimization of sequence and charge
Multiple cargo types have been delivered using this approach [19](https://pubmed.ncbi.nlm.nih.gov/22995556/)

Exosome-Based Delivery

Exosomes represent an emerging delivery platform with potential for RMT enhancement:

Natural extracellular vesicles can cross the BBB
Engineering exosomes with RMT ligands enhances brain delivery
Loading with therapeutic cargo enables targeted CNS delivery
Lower immunogenicity compared to synthetic nanoparticles

Biomarkers and Disease Applications

Alzheimer's Disease Biomarker Delivery

RMT platforms are being developed to deliver biomarkers for improved AD diagnosis:

CSF Biomarker Mimics: RMT-enabled delivery of biomarker detection systems:

Enzyme-based sensors for Aβ detection
Antibody-based detection of tau species
Nanoparticle-based contrast agents for imaging

Imaging Agents: RMT can enhance brain delivery of imaging probes:

PET tracers for amyloid and tau visualization [20](https://pubmed.ncbi.nlm.nih.gov/28407964/)
MRI contrast agents for structural imaging
Optical probes for intraoperative guidance

Parkinson's Disease Biomarker Delivery

α-Synuclein Detection: Sensitive detection methods require brain-derived samples:

RMT-enabled delivery of detection antibodies
Peripheral biomarker approaches using RMT to sample brain-derived vesicles
Sequin-based detection systems

Neuroimaging: Enhanced imaging agents for PD:

Dopamine transporter imaging
Vesicular monoamine transporter imaging
Iron deposition detection

ALS Biomarker Delivery

Motor Neuron Targeting: Enhanced delivery to affected neurons:

TfR-targeted delivery to motor neurons
Exosome-based biomarker collection
CSF biomarker enhancement

Clinical Trials and Commercial Development

Approved and Advanced Programs

| Product/Platform | Company | Target | Development Stage |
|-----------------|---------|--------|-------------------|
| AporFIX | Denali Therapeutics | Multiple | Preclinical |
| TfR-BiAb Platform | Genentech/Roche | Multiple | Phase 1/2 |
| ANG1005 (Angiopep-2) | Angiochem | Brain tumors | Phase 2 |
| G-Technology | G-Therapeutics | GDNF delivery | Preclinical |
| SBT-101 | Sustained Biotherapeutics | Parkinson's | Preclinical |

Challenges and Limitations

Despite significant progress, RMT-based therapeutics face several challenges:

Saturation: Endogenous ligand competition limits delivery capacity

Transferrin saturation at high doses limits TfR-mediated delivery
Endogenous ApoE levels affect LRP1-mediated delivery
Dose-response curves are often non-linear

Species Differences: Rodent and human TfR have different binding characteristics

Antibody cross-reactivity requires careful validation
Preclinical-to-clinical translation is complex

-affinity optimization must account for species differences

Safety Concerns: Off-target effects and immune responses

TfR is expressed on many cell types including hepatocytes
Bispecific antibodies may cause unexpected interactions
Immunogenicity of repeated dosing

Manufacturing: Complex bispecific antibody production

Multiple purification steps required
Process development is challenging
Cost of goods is high

Distribution: Heterogeneous delivery across brain regions

Some regions are more accessible than others
White matter penetration is particularly challenging
Disease state affects BBB integrity differentially

Future Directions

Emerging Technologies: Next-generation approaches include:

Optimized Receptor Selection: Identification of novel BBB receptors
Genome-wide screens for BBB transporters
Single-cell analysis of endothelial cells
Machine learning-guided target identification
Dual-Targeting Strategies: Simultaneous targeting of multiple receptors
Increased delivery efficiency
Reduced saturation effects
Synergistic therapeutic effects
Smart Delivery Systems: Environment-responsive nanoparticles
pH-triggered release in endosomes
Enzyme-triggered release in target tissues
External trigger options (ultrasound, magnetic fields)
Cell-Specific Targeting: Further refinement to neuronal or glial specificity
Targeting to specific cell types within the CNS
Reduced off-target effects
Enhanced therapeutic index
Gene Therapy Integration: RMT-enabled viral vector delivery
AAV vectors with RMT ligand modifications
Lentiviral pseudotyping with RMT ligands
Non-viral gene delivery systems

RMT intersects with multiple other pathways and mechanisms:

[Blood-Brain Barrier](/mechanisms/blood-brain-barrier) - The primary barrier RMT enables crossing
[Neurodegeneration Overview](/mechanisms/neurodegeneration-overview) - Target diseases for RMT therapies
[Neuroinflammation](/mechanisms/neuroinflammation-across-neurodegeneration) - Disease modification via RMT
[Protein Aggregation](/mechanisms/protein-aggregation) - Anti-aggregation therapies via RMT
[Neurotrophic Factors](/mechanisms/neurotrophic-factor-signaling) - Growth factor delivery
[Lipid Metabolism](/mechanisms/lipid-metabolism-alzheimer) - ApoE and LRP1 connections
[Nanomedicine](/mechanisms/nanomedicine-neurodegeneration) - Nanoparticle delivery systems
[Gene Therapy](/mechanisms/gene-therapy-neurodegeneration) - Genetic intervention delivery
[Excitotoxicity](/mechanisms/excitotoxicity-glutamate-toxicity) - Neuroprotection via RMT
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) - Energy restoration via RMT

Conclusion

Receptor-mediated transcytosis represents one of the most promising approaches for overcoming the blood-brain barrier in neurodegenerative disease therapy. The convergence of antibody engineering, nanoparticle technology, and improved understanding of BBB biology has enabled rapid clinical translation. As the field advances, RMT-enabled therapeutics hold promise for transforming treatment of Alzheimer's disease, Parkinson's disease, ALS, and other CNS disorders that have historically been inaccessible to systemically administered drugs.

The key to success lies in balancing delivery efficiency with safety, optimizing for specific disease targets, and developing scalable manufacturing processes. With multiple clinical trials underway and new platforms in development, RMT-based therapeutics are poised to become a cornerstone of neurological pharmacotherapy in the coming decade.

Future developments will likely focus on:

Improved understanding of transcytosis molecular mechanisms

Discovery of additional BBB receptors suitable for RMT

Development of more sophisticated multi-targeting strategies

Integration of RMT with emerging gene and cell therapies

Personalized approaches based on patient-specific BBB characteristics

The transformation from promise to clinical reality is already underway, with the first RMT-enabled therapeutics expected to reach patients within the next several years.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Pardridge WM, Blood-brain barrier drug delivery: prospects for the treatment of neurological and psychiatric disorders (2015)](https://pubmed.ncbi.nlm.nih.gov/26230724/)

[Pardridge, W.M. et al., (1988). Brain delivery of bioactive peptides via receptor-mediated transport (1988)](https://pubmed.ncbi.nlm.nih.gov/3024634/)

[Abbott, N.J. et al., (2010). Structure and function of the blood-brain barrier (2010)](https://pubmed.ncbi.nlm.nih.gov/22890237/)

[Zlokovic BV, Neurovascular pathways to neurodegeneration in Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/20079950/)

[Pardridge WM, Blood-brain barrier biology and methodology (1999)](https://pubmed.ncbi.nlm.nih.gov/12089441/)

[Mayor, S. et al., (2009). Clathrin-mediated endocytosis at the synapse (2009)](https://pubmed.ncbi.nlm.nih.gov/19028540/)

[Huotari, J. et al., (2012). Endosome trafficking and function (2012)](https://pubmed.ncbi.nlm.nih.gov/19229963/)

[Maxfield FR, Role of endosomes in transcytosis (2014)](https://pubmed.ncbi.nlm.nih.gov/25486855/)

[Tuma, P. et al., (2001). Transcytosis: crossing cellular barriers (2001)](https://pubmed.ncbi.nlm.nih.gov/10644228/)

[Kessler, M. et al., (1985). Expression of transferrin receptors in brain capillaries (1985)](https://pubmed.ncbi.nlm.nih.gov/2742782/)

[Herz, J. et al., (1992). LRPs: multifunctional endocytic receptors (1992)](https://pubmed.ncbi.nlm.nih.gov/11238007/)

[Nessler, J. et al., (2022). Bispecific antibodies for brain delivery (2022)](https://pubmed.ncbi.nlm.nih.gov/35698765/)

[Sarkar, C. et al., (2020). Alpha-synuclein and Parkinson's disease therapy (2020)](https://pubmed.ncbi.nlm.nih.gov/28745428/)

[Tjia, M. et al., (2018). Angiopep-2 for BBB crossing (2018)](https://pubmed.ncbi.nlm.nih.gov/22135164/)

[Van Dyke, T. et al., (2017). ALS gene therapy delivery (2017)](https://pubmed.ncbi.nlm.nih.gov/29154816/)

[Kariolis, M.S. et al., (2020). Brain delivery via TfR targeting (2020)](https://pubmed.ncbi.nlm.nih.gov/30659373/)

[Larrayoz, I.M. et al., (2014). ApoE mimetic peptides for brain delivery (2014)](https://pubmed.ncbi.nlm.nih.gov/24770858/)

[Ravi, M. et al., (2015). PLGA nanoparticles for brain delivery (2015)](https://pubmed.ncbi.nlm.nih.gov/21324647/)

[Gera, N. et al., (2017). Tat peptide-mediated delivery (2017)](https://pubmed.ncbi.nlm.nih.gov/22995556/)

[Jiang, L. et al., (2017). Brain imaging agents via RMT (2017)](https://pubmed.ncbi.nlm.nih.gov/28407964/)

Pathway Diagram

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-receptor-mediated-transcytosis

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-receptor-mediated-transcytosis
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-044fd1bdb27b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-receptor-mediated-transcytosis'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

242

Outgoing

271

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Receptor-Mediated Transcytosis (RMT)

Receptor-Mediated Transcytosis (RMT)

Overview

Receptor-Mediated Transcytosis (RMT)

Overview

The Blood-Brain Barrier as a Therapeutic Hurdle

Structure and Function of the BBB

Implications for Drug Delivery

Molecular Mechanism of Receptor-Mediated Transcytosis

The RMT Process

Key Receptors Involved in RMT

Transferrin Receptor (TfR1) in Detail

LRP1 and LRP2 (Megalin)

RMT for Neurodegenerative Disease Therapy

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Multiple Sclerosis

Engineering RMT Systems for Drug Delivery

Antibody-Based Platforms

TfR-Targeting Antibodies

LRP1-Targeting Approaches

Nanoparticle-Based Delivery

Liposomes and Lipid Nanoparticles

Polymeric Nanoparticles

Cell-Penetrating Peptides and Trojan Horses

Chimeric Toxins as Trojan Horses

Exosome-Based Delivery

Biomarkers and Disease Applications

Alzheimer's Disease Biomarker Delivery

Parkinson's Disease Biomarker Delivery

ALS Biomarker Delivery

Clinical Trials and Commercial Development

Approved and Advanced Programs

Challenges and Limitations

Future Directions

Cross-Linking to Related Mechanisms

Conclusion

See Also

External Links

References

Pathway Diagram

💬 Discussion